Active, not recruitingNCT06275724
Specified Drug-use Survey of Leqvio for s.c. Injection.
Studying Homozygous familial hypercholesterolemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Principal Investigator
- Novartis PharmaceuticalsNovartis Pharmaceuticals
- Intervention
- inclisiran(other)
- Enrollment
- 585 enrolled
- Eligibility
- 15-100 years · All sexes
- Timeline
- 2024 – 2026
Study locations (30)
- Novartis Investigative Site, Handa, Aichi-ken, Japan
- Novartis Investigative Site, Ichinomiya, Aichi-ken, Japan
- Novartis Investigative Site, Komaki, Aichi-ken, Japan
- Novartis Investigative Site, Nagoya, Aichi-ken, Japan
- Novartis Investigative Site, Toyoake, Aichi-ken, Japan
- Novartis Investigative Site, Tsushima, Aichi-ken, Japan
- Novartis Investigative Site, Asahi, Chiba, Japan
- Novartis Investigative Site, Inzai, Chiba, Japan
- Novartis Investigative Site, Urayasu, Chiba, Japan
- Novartis Investigative Site, Matsuyama, Ehime, Japan
- Novartis Investigative Site, Fukui-shi, Fukui, Japan
- Novartis Investigative Site, Fukuoka, Fukuoka, Japan
- Novartis Investigative Site, Kitakyushu, Fukuoka, Japan
- Novartis Investigative Site, Fukushima, Fukushima, Japan
- Novartis Investigative Site, Kōriyama, Fukushima, Japan
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06275724 on ClinicalTrials.govOther trials for Homozygous familial hypercholesterolemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07447648Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)
- RECRUITINGPHASE2NCT07489209A Dose-exploration Study of EDP167 in HoFHEddingpharm (Zhuhai) Co., Ltd.
- RECRUITINGPHASE3NCT07037771A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)Arrowhead Pharmaceuticals
- RECRUITINGNANCT06743659Computerized Decision Support for Identification and Management of Familial HypercholesterolemiaBrigham and Women's Hospital
- ACTIVE NOT RECRUITINGPHASE3NCT06712771A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of VSA003 in Chinese HoFH PatientsVisirna Therapeutics HK Limited
- ACTIVE NOT RECRUITINGNCT06832371Evaluation of the Effect of Lomitapide Treatment on Major Adverse Cardiovascular Events (MACE) in Patients With Homozygous Familial HypercholesterolemiaFondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)
- RECRUITINGEARLY PHASE1NCT06458010Clinical Exploration Trial of YOLT-101 in the Treatment of Familial Hypercholesterolemia (FH)RenJi Hospital
- RECRUITINGEARLY PHASE1NCT06125847NGGT006 Gene Therapy for Homozygous Familial HypercholesterolemiaFirst Affiliated Hospital Xi'an Jiaotong University
See all trials for Homozygous familial hypercholesterolemia →